At Intarcia, through the passion and commitment of our employees, we seek to leverage our technologies in drug development and delivery to provide improved therapeutic outcomes for patients and to help patients achieve a better quality of life. We develop treatments that are more conveniently administered to optimize therapeutic benefits and reduce adverse effects for chronic and life-threatening diseases. Our exclusive approach is enabled by a novel continous subcutaneous delivery technology that allows for constant and consistent delivery of a targeted amount of drug exposure, achieving optimal drug levels while improving the side effect profile.
The field of biotechnology has paved the way for the discovery of new protein- and peptide-based therapies for chronic, debilitating and potentially life-threatening diseases. However, these treatments often require long-term therapy, frequent injections and induce side effects that may limit the treatment's therapeutic potential. Intarcia's drug development approach is unique due to our ability to stabilize macromolecules at human body temperature and to deliver them on a consistent, long-term and continuous basis, which allows for more convenient delivery of treatment with enhanced therapeutic benefits and reduced treatment-limiting side effects. Further, should early withdrawal of therapy be required due to drug-related side effects, unlike most extended delivery formulations, Intarcia's mini pump can be quickly and safely removed decreasing drug concentrations to undetectable levels within hours.
Our integrated and experienced team of dedicated professionals has successfully developed new drugs and possesses expertise in all phases of drug development from preclinical and clinical development through regulatory and marketing approval. Currently, our drug development team is working to maximize the value of our technology by moving our therapeutic candidates through clinical trials.
Developing Products with Significant Market Potential
Intarcia strives to develop product candidates with a demonstrated potential to deliver significant therapeutic improvements over existing therapies. We focus on therapies that address significant unmet medical needs and represent large commercial opportunities. The therapies we are developing:
By targeting product candidates from proven therapeutic classes and existing safety and clinical data, our development approach allows us to mitigate risks while reducing the cost and time required for developing products. If we are able to complete product development with fewer clinical trials than are required for a new therapeutic, we may have lower development costs and shorter timelines. By delivering these product candidates with zero-order kinetics facilitated by Intarcia's mini-pump technology, we believe we can deliver therapy with a truly optimized therapeutic index.
Maximizing the Potential of Intarcia's Technology Platform
Intarcia's technology allows for drug delivery with zero-order kinetics. The benefits of Intarcia's delivery systems are:
Maximizing Commercial Potential of Our Technology
With the added validation of Intarcia's technology in the ITCA 650 type 2 diabetes program, we continue to evaluate new opportunities for novel and proprietary product candidates, with efforts focused around two areas:
Intarcia continues to evaluate new opportunities for novel and proprietary product candidates, with efforts focused around two areas:
To discuss opportunities, please contact our business development and licensing office at (510) 723-3438.
Intarcia's lead product candidate, ITCA 650 is being developed for the treatment of Type 2 Diabetes and employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy.